Amphastar Pharmaceuticals, Inc. — Cyborg Score 5/10
Mixed
Specialty Pharmaceuticals / Complex Generics and Proprietary Injectables
Strategic Profile
The company projects that proprietary and biosimilar products will represent 85% of its pipeline by 2026, reflecting management's conviction that the company's future lies in complex, differentiated therapies rather than commodity generics. Amphastar's vertically integrated manufacturing capabilities and technical expertise in peptides, inhalation products, and biosimilars provide a competitive advantage, offering quality control advantages and potentially faster development timelines.
Cyborg Score Rationale
AMPH's legacy generics are declining, branded products face growth deceleration, and margins are pressured by product mix and rising R&D/SG&A costs, with FY26 revenue guidance cut to mid- to high-single-digit growth. While the pipeline transformation is strategically sound, near-term execution challenges and margin pressures create uncertainty.
Top Insights
BAQSIMI generated $185.4 million in revenue for 2025, up 12% year-over-year, driven by higher U.S. unit volumes and the transition to direct global distribution.
FDA approvals for iron sucrose, teriparatide, and Ipratropium Bromide HFA (AMP-007) with 180 days of generic drug exclusivity position the company for growth, with ipratropium launch expected early Q2 2026.
Q4 2025 revenue of $183.1 million declined 1.8% year-over-year and missed expectations, while adjusted EPS of $0.73 fell below consensus.
R&D spending is expected to increase further as clinical programs advance and the peptide portfolio moves toward the clinic, necessary to support technical complexity spanning multiple delivery mechanisms.
Named Competitors
Glucagon generics — Competitive generic pressure on Amphastar's legacy products
Epinephrine/Naloxone generics — Long-established competition in emergency injectable space
BAQSIMI direct competitor — Proprietary glucagon alternative for diabetes management
Recent Developments
(February 2026) FDA approval of Ipratropium Bromide HFA with 180-day generic exclusivity; early Q2 2026 commercial launch expected as largest growth driver
(December 2025) Q4 2025 earnings miss with 1.8% revenue decline and operating margin contraction to 19.4%; FY26 guidance cut to mid-to-high single-digit growth
(December 2025) Teriparatide (AMP-015) launch with market exceeding $500 million; expected meaningful contribution in 2026
(August 2025) Iron sucrose FDA approval and launch; contributed $4.4 million since launch
Open the full interactive Amphastar Pharmaceuticals, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.